Literature DB >> 20538341

New treatment guidelines for acute bipolar depression: a systematic review.

Alessandra M A Nivoli1, Francesc Colom, Andrea Murru, Isabella Pacchiarotti, Piero Castro-Loli, Ana González-Pinto, Kostas N Fountoulakis, Eduard Vieta.   

Abstract

INTRODUCTION: Bipolar depression poses a great burden on patients and their families due to its duration, associated functional impairment, and limited treatment options. Given the complexity of the disorder and the advances in treatment, a number of clinical guidelines, consensus statements and expert opinions were developed with the aim to standardize treatment and provide clinicians with treatment algorithms for every-day clinical practice. Unfortunately, they often led to conflicting conclusions and recommendations due to limitations of the available literature. As findings emerge from research literature, guidelines quickly become obsolete and need to be updated or revised. Many guidelines have been updated in the last 5 years, after the last review of bipolar disorder (BD) treatment guidelines.
OBJECTIVE: The purpose of this work is to systematically review guidelines, consensus meetings and treatment algorithms on the acute treatment of bipolar depression updated or published since 2005, to critically underline common and critical points, highlight limits and strengths, and provide a starting point for future research
MATERIALS AND METHODS: The MEDLINe/PubMed/Index Medicus, PsycINFO/PsycLIT, Excerpta Medica/EMBASE, databases were searched using "depression", "bipolar", "manic-depression", "manic-depressive" and "treatment guidelines" as key words
RESULTS: The search returned 204 articles. Amongst them, there were 28 papers concerning structured treatment algorithms and/or guidelines suggested by official panels. After excluding those guidelines that were not performed by scientific societies or international groups and those published before 2005, the final selection yielded 7 papers When looking into guidelines content, the results indicate a trend to the gradual acceptance of the use of the atypical antipsychotic quetiapine as monotherapy as first-line treatment. Antidepressant monotherapy is discouraged in most of them, although some support the use of antidepressants in combination with antimanic agents for a limited period of time. Lamotrigine has become a highly controversial option.
CONCLUSION: The management of bipolar depression is complex and should be differentiated from management of unipolar depression. Guidelines may be useful instruments for helping clinicians to choose and plan bipolar depression treatment by integrating the more updated scientific knowledge with every-day clinical practice and patient-specific factors; however, a further effort is needed in order to improve guidelines implementation in clinical practice. The latest updates on treatment guidelines for bipolar depression give priority to novel treatment approaches, such as quetiapine, over more traditional ones, such as lithium or antidepressants. Lamotrigine is a controversial option.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538341     DOI: 10.1016/j.jad.2010.05.018

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  33 in total

Review 1.  Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders.

Authors:  O V Forlenza; V J R De-Paula; B S O Diniz
Journal:  ACS Chem Neurosci       Date:  2014-05-06       Impact factor: 4.418

Review 2.  Management of adverse effects of mood stabilizers.

Authors:  Andrea Murru; Dina Popovic; Isabella Pacchiarotti; Diego Hidalgo; Jordi León-Caballero; Eduard Vieta
Journal:  Curr Psychiatry Rep       Date:  2015-08       Impact factor: 5.285

Review 3.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

Review 4.  The presentation, recognition and management of bipolar depression in primary care.

Authors:  Joseph M Cerimele; Lydia A Chwastiak; Ya-Fen Chan; David A Harrison; Jürgen Unützer
Journal:  J Gen Intern Med       Date:  2013-12       Impact factor: 5.128

5.  Short-term venlafaxine v. lithium monotherapy for bipolar type II major depressive episodes: effectiveness and mood conversion rate.

Authors:  Jay D Amsterdam; Lorenzo Lorenzo-Luaces; Irene Soeller; Susan Qing Li; Jun J Mao; Robert J DeRubeis
Journal:  Br J Psychiatry       Date:  2016-02-18       Impact factor: 9.319

Review 6.  Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis.

Authors:  Eduard Vieta; Marc Valentí
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

7.  Unrecognised bipolar disorder among UK primary care patients prescribed antidepressants: an observational study.

Authors:  Tom Hughes; Alastair Cardno; Robert West; Federica Marino-Francis; Imogen Featherstone; Keeley Rolling; Alice Locker; Kate McLintock; Allan House
Journal:  Br J Gen Pract       Date:  2016-01-06       Impact factor: 5.386

Review 8.  A systematic review of the evidence for the treatment of acute depression in bipolar I disorder.

Authors:  Michael A Cerullo; Stephen M Strakowski
Journal:  CNS Spectr       Date:  2013-03-18       Impact factor: 3.790

9.  Symptom severity, self-reported adherence, and electronic pill monitoring in poorly adherent patients with bipolar disorder.

Authors:  Martha Sajatovic; Jennifer B Levin; Johnny Sams; Kristin A Cassidy; Kouri Akagi; Michelle E Aebi; Luis F Ramirez; Steven A Safren; Curtis Tatsuoka
Journal:  Bipolar Disord       Date:  2015-09       Impact factor: 6.744

10.  The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders.

Authors:  Isabella Pacchiarotti; David J Bond; Ross J Baldessarini; Willem A Nolen; Heinz Grunze; Rasmus W Licht; Robert M Post; Michael Berk; Guy M Goodwin; Gary S Sachs; Leonardo Tondo; Robert L Findling; Eric A Youngstrom; Mauricio Tohen; Juan Undurraga; Ana González-Pinto; Joseph F Goldberg; Ayşegül Yildiz; Lori L Altshuler; Joseph R Calabrese; Philip B Mitchell; Michael E Thase; Athanasios Koukopoulos; Francesc Colom; Mark A Frye; Gin S Malhi; Konstantinos N Fountoulakis; Gustavo Vázquez; Roy H Perlis; Terence A Ketter; Frederick Cassidy; Hagop Akiskal; Jean-Michel Azorin; Marc Valentí; Diego Hidalgo Mazzei; Beny Lafer; Tadafumi Kato; Lorenzo Mazzarini; Anabel Martínez-Aran; Gordon Parker; Daniel Souery; Ayşegül Ozerdem; Susan L McElroy; Paolo Girardi; Michael Bauer; Lakshmi N Yatham; Carlos A Zarate; Andrew A Nierenberg; Boris Birmaher; Shigenobu Kanba; Rif S El-Mallakh; Alessandro Serretti; Zoltan Rihmer; Allan H Young; Georgios D Kotzalidis; Glenda M MacQueen; Charles L Bowden; S Nassir Ghaemi; Carlos Lopez-Jaramillo; Janusz Rybakowski; Kyooseob Ha; Giulio Perugi; Siegfried Kasper; Jay D Amsterdam; Robert M Hirschfeld; Flávio Kapczinski; Eduard Vieta
Journal:  Am J Psychiatry       Date:  2013-11       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.